Policy Options to Mitigate Gilead's $1,000 Hepaitis C Pill: A Conversation with Chris Dawe (July 10th)
www.thehealthcarepolicypodcast.com
Listen Now Late last year Gilead Sciences received FDA approval for its Hepatitis C drug Solvaldi. Hepatitis C (Hep C) affects three to four million Americans and can have serious health consequences. Gilead priced the drug at $1,000 a pill or between $84,000 and $168,000 for the full, curative treatment (effective in approximately 90% of patients). However as priced if every Hep C patient received Solvaldi the cost would equal the combined annual spending amount for all drugs sold in the US.
Policy Options to Mitigate Gilead's $1,000 Hepaitis C Pill: A Conversation with Chris Dawe (July 10th)
Policy Options to Mitigate Gilead's $1,000…
Policy Options to Mitigate Gilead's $1,000 Hepaitis C Pill: A Conversation with Chris Dawe (July 10th)
Listen Now Late last year Gilead Sciences received FDA approval for its Hepatitis C drug Solvaldi. Hepatitis C (Hep C) affects three to four million Americans and can have serious health consequences. Gilead priced the drug at $1,000 a pill or between $84,000 and $168,000 for the full, curative treatment (effective in approximately 90% of patients). However as priced if every Hep C patient received Solvaldi the cost would equal the combined annual spending amount for all drugs sold in the US.